Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

VNLPY:US

1.4600 USD 0.0500 3.55%

As of 20:10:05 ET on 01/16/2015.

Snapshot for Vernalis PLC (VNLPY)

Open: 1.4600 Day's Range: 1.4600 - 1.4600 Volume: 1,500
Previous Close: 1.4100 52wk Range: 1.0000 - 1.7100 1-Yr Rtn: -

Stock Chart for VNLPY

No chart data available.
  • VNLPY:US 1.4600
  • 1D
  • 1M
  • 1Y
1.4100
Interactive VNLPY Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VNLPY

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (GBP) (ttm) -
Est. EPS (GBP) (12/2014) -0.0400
Est. PEG Ratio -
Market Cap (M USD) 322.88
Shares Outstanding (M) 221.15
30 Day Average Volume 153
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 48.0400
Dividend Ex-Date 07/08/1996
5 Year Dividend Growth -
Next Earnings Announcement 02/10/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VNLPY

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for VNLPY

Vernalis plc is a revenue generating development stage pharmaceutical company which has a broad pipeline of research and development programs. The Company is focused on developing products for the US prescription cough and cold market. The Company derives pipeline candidates both from collaborations with global pharmaceutical businesses and their own research activities.

Ian GarlandChief Executive OfficerDavid MackneyChief Financial Officer
Tom ParkerSenior VP:Commercial OperationsPascal BorderiesSenior VP:Medical Affairs
More Company Profile & Key Executives for VNLPY

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil